Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contribution of PEPFAR-Supported HIV and TB Molecular Diagnostic Networks to COVID-19 Testing Preparedness in 16 Countries.
Romano ER, Sleeman K, Hall-Eidson P, Zeh C, Bhairavabhotla R, Zhang G, Adhikari A, Alemnji G, Cardo YR, Pinheiro A, Pocongo B, Eno LT, Shang JD, Ndongmo CB, Rosario H, Moreno O, De León LAC, Fonjungo P, Kabwe C, Ahuke-Mundeke S, Gama D, Dlamini S, Maphalala G, Abreha T, Purfield A, Gebrehiwot YT, Desalegn DM, Basiye F, Mwangi J, Bowen N, Mengistu Y, Lecher S, Kampira E, Kaba M, Bitilinyu-Bangoh J, Masamha G, Viegas SO, Beard RS, van Rooyen G, Shiningavamwe AN, I J M, Iriemenam NC, Mba N, Okoi C, Katoro J, Kenyi DL, Bior BK, Mwangi C, Nabadda S, Kaleebu P, Yingst SL, Chikwanda P, Veri L, Simbi R, Alexander H. Romano ER, et al. Among authors: kaleebu p. Emerg Infect Dis. 2022 Dec;28(13):S59-S68. doi: 10.3201/eid2813.220789. Emerg Infect Dis. 2022. PMID: 36502414 Free PMC article. Review.
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Ndembi N, et al. Among authors: kaleebu p. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. J Infect Dis. 2010. PMID: 19938977 Clinical Trial.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Lancet Infect Dis. 2024 May 28:S1473-3099(24)00289-5. doi: 10.1016/S1473-3099(24)00289-5. Online ahead of print. Lancet Infect Dis. 2024. PMID: 38821073
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.
Serwanga J, Kato L, Oluka GK, Ankunda V, Sembera J, Baine C, Kitabye I, Namuyanja A, Opio S, Katende JS, Ejou P; COVID-19 Immunoprofiling Team; Kaleebu P. Serwanga J, et al. Among authors: kaleebu p. Front Immunol. 2024 May 8;15:1384668. doi: 10.3389/fimmu.2024.1384668. eCollection 2024. Front Immunol. 2024. PMID: 38779677 Free PMC article.
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response.
Mentzer AJ, Dilthey AT, Pollard M, Gurdasani D, Karakoc E, Carstensen T, Muhwezi A, Cutland C, Diarra A, da Silva Antunes R, Paul S, Smits G, Wareing S, Kim H, Pomilla C, Chong AY, Brandt DYC, Nielsen R, Neaves S, Timpson N, Crinklaw A, Lindestam Arlehamn CS, Rautanen A, Kizito D, Parks T, Auckland K, Elliott KE, Mills T, Ewer K, Edwards N, Fatumo S, Webb E, Peacock S, Jeffery K, van der Klis FRM, Kaleebu P, Vijayanand P, Peters B, Sette A, Cereb N, Sirima S, Madhi SA, Elliott AM, McVean G, Hill AVS, Sandhu MS. Mentzer AJ, et al. Among authors: kaleebu p. Nat Med. 2024 May;30(5):1384-1394. doi: 10.1038/s41591-024-02944-5. Epub 2024 May 13. Nat Med. 2024. PMID: 38740997 Free PMC article.
Viruses associated with measles-like illnesses in Uganda.
Namuwulya P, Ashraf S, Niebel M, Ssekagiri A, Tushabe P, Kakooza P, Tong L, Bukenya H, Jerome H, Davis C, Birungi M, Turyahabwe I, Mugaga A, Eliku JP, Francis A, Nakabazzi L, Nsubuga F, Katushabe E, Kisakye A, Ampeire I, Nanteza A, Kaleebu P, Bakamutumaho B, Nsamba P, Kazibwe A, da Silva Filipe A, Tweyongyere R, Bwogi J, Thomson EC. Namuwulya P, et al. Among authors: kaleebu p. J Infect. 2024 May;88(5):106148. doi: 10.1016/j.jinf.2024.106148. Epub 2024 Apr 6. J Infect. 2024. PMID: 38588959 Free PMC article.
HLA-A*23 Is Associated With Lower Odds of Acute Retroviral Syndrome in Human Immunodeficiency Virus Type 1 Infection: A Multicenter Sub-Saharan African Study.
Lindquist L, Kilembe W, Karita E, Price MA, Kamali A, Kaleebu P, Tang J, Allen S, Hunter E, Gilmour J, Rowland-Jones SL, Sanders EJ, Hassan AS, Esbjörnsson J. Lindquist L, et al. Among authors: kaleebu p. Open Forum Infect Dis. 2024 Mar 13;11(4):ofae129. doi: 10.1093/ofid/ofae129. eCollection 2024 Apr. Open Forum Infect Dis. 2024. PMID: 38560608 Free PMC article.
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.
Ankunda V, Katende JS, Oluka GK, Sembera J, Baine C, Odoch G, Ejou P, Kato L; COVID-19 Immunoprofiling Team; Kaleebu P, Serwanga J. Ankunda V, et al. Among authors: kaleebu p. Front Immunol. 2024 Feb 16;15:1325387. doi: 10.3389/fimmu.2024.1325387. eCollection 2024. Front Immunol. 2024. PMID: 38469296 Free PMC article.
399 results